Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

Toyoshi Yanagihara, Kunihiro Suzuki, Ayaka Egashira, Naruhiko Ogo, Tatsuma Asoh, Tsukasa Nara, Kensaku Takatsuki, Seiji Yoshizawa, Sy Giin Chong, Naoki Hamada, Takashige Maeyama

研究成果: Contribution to journalArticle査読

1 被引用数 (Scopus)

抄録

We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just been approved for treatment of progressive fibrosing ILD, but to date, no reports of RP-ILD treated with nintedanib have been published. This case report may advance discussions regarding the use and timing of nintedanib in treating RP-ILD.

本文言語英語
論文番号101272
ジャーナルRespiratory Medicine Case Reports
31
DOI
出版ステータス出版済み - 1 2020

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

フィンガープリント 「Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル